Literature DB >> 23815307

Arrestin-dependent but G-protein coupled receptor kinase-independent uncoupling of D2-dopamine receptors.

Jeremy Celver1, Meenakshi Sharma, Vaidehi Thanawala, J Christopher Octeau, Abraham Kovoor.   

Abstract

We reconstituted D2 like dopamine receptor (D2R) and the delta opioid receptor (DOR) coupling to G-protein gated inwardly rectifying potassium channels (K(ir)3) and directly compared the effects of co-expression of G-protein coupled receptor kinase (GRK) and arrestin on agonist-dependent desensitization of the receptor response. We found, as described previously, that co-expression of a GRK and an arrestin synergistically increased the rate of agonist-dependent desensitization of DOR. In contrast, only arrestin expression was required to produce desensitization of D2R responses. Furthermore, arrestin-dependent GRK-independent desensitization of D2R-K(ir)3 coupling could be transferred to DOR by substituting the third cytoplasmic loop of DOR with that of D2R. The arrestin-dependent GRK-independent desensitization of D2R desensitization was inhibited by staurosporine treatment, and blocked by alanine substitution of putative protein kinase C phosphorylation sites in the third cytoplasmic loop of D2R. Finally, the D2R construct in which putative protein kinase C phosphorylation sites were mutated did not undergo significant agonist-dependent desensitization even after GRK co-expression, suggesting that GRK phosphorylation of D2R does not play an important role in uncoupling of the receptor.
© 2013 International Society for Neurochemistry.

Entities:  

Keywords:  D2 dopamine receptor; G-protein coupled receptor kinase; arrestin; desensitization; protein kinase C; uncoupling

Mesh:

Substances:

Year:  2013        PMID: 23815307      PMCID: PMC4825321          DOI: 10.1111/jnc.12359

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  35 in total

Review 1.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

2.  Mu and delta opioid receptors are differentially desensitized by the coexpression of beta-adrenergic receptor kinase 2 and beta-arrestin 2 in xenopus oocytes.

Authors:  A Kovoor; V Nappey; B L Kieffer; C Chavkin
Journal:  J Biol Chem       Date:  1997-10-31       Impact factor: 5.157

Review 3.  The structural basis of arrestin-mediated regulation of G-protein-coupled receptors.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Pharmacol Ther       Date:  2006-02-03       Impact factor: 12.310

4.  Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?

Authors:  Christopher S Kearn; Katherine Blake-Palmer; Emma Daniel; Ken Mackie; Michelle Glass
Journal:  Mol Pharmacol       Date:  2005-02-14       Impact factor: 4.436

Review 5.  Dyskinesia: L-dopa-induced and tardive dyskinesia.

Authors:  O Rascol; N Fabre
Journal:  Clin Neuropharmacol       Date:  2001 Nov-Dec       Impact factor: 1.592

6.  N-formyl peptide receptor phosphorylation domains differentially regulate arrestin and agonist affinity.

Authors:  T Alexander Key; Terry D Foutz; Vsevolod V Gurevich; Larry A Sklar; Eric R Prossnitz
Journal:  J Biol Chem       Date:  2002-11-06       Impact factor: 5.157

7.  Aspartic acid 564 in the third cytoplasmic loop of the luteinizing hormone/choriogonadotropin receptor is crucial for phosphorylation-independent interaction with arrestin2.

Authors:  Sutapa Mukherjee; Vsevolod V Gurevich; Anita Preninger; Heidi E Hamm; Marie-France Bader; Asgerally T Fazleabas; Lutz Birnbaumer; Mary Hunzicker-Dunn
Journal:  J Biol Chem       Date:  2002-02-26       Impact factor: 5.157

8.  Heterologous activation of protein kinase C stimulates phosphorylation of delta-opioid receptor at serine 344, resulting in beta-arrestin- and clathrin-mediated receptor internalization.

Authors:  B Xiang; G H Yu; J Guo; L Chen; W Hu; G Pei; L Ma
Journal:  J Biol Chem       Date:  2000-11-20       Impact factor: 5.157

9.  Distinct domains of the mu-opioid receptor control uncoupling and internalization.

Authors:  Jeremy Celver; Mei Xu; Wenzhen Jin; Janet Lowe; Charles Chavkin
Journal:  Mol Pharmacol       Date:  2004-03       Impact factor: 4.436

10.  Agonist-induced desensitization of the mu opioid receptor-coupled potassium channel (GIRK1).

Authors:  A Kovoor; D J Henry; C Chavkin
Journal:  J Biol Chem       Date:  1995-01-13       Impact factor: 5.157

View more
  6 in total

1.  Elucidation of G-protein and β-arrestin functional selectivity at the dopamine D2 receptor.

Authors:  Sean M Peterson; Thomas F Pack; Angela D Wilkins; Nikhil M Urs; Daniel J Urban; Caroline E Bass; Olivier Lichtarge; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-11       Impact factor: 11.205

2.  AMP-activated protein kinase slows D2 dopamine autoreceptor desensitization in substantia nigra neurons.

Authors:  Wei Yang; Adam C Munhall; Steven W Johnson
Journal:  Neuropharmacology       Date:  2019-07-10       Impact factor: 5.250

Review 3.  Opioid receptor desensitization: mechanisms and its link to tolerance.

Authors:  Stéphane Allouche; Florence Noble; Nicolas Marie
Journal:  Front Pharmacol       Date:  2014-12-18       Impact factor: 5.810

4.  Desensitized D2 autoreceptors are resistant to trafficking.

Authors:  Brooks G Robinson; James R Bunzow; Jonathan B Grimm; Luke D Lavis; Joshua T Dudman; Jennifer Brown; Kim A Neve; John T Williams
Journal:  Sci Rep       Date:  2017-06-29       Impact factor: 4.379

Review 5.  GRKs as Modulators of Neurotransmitter Receptors.

Authors:  Eugenia V Gurevich; Vsevolod V Gurevich
Journal:  Cells       Date:  2020-12-31       Impact factor: 6.600

6.  G protein beta 5 is targeted to D2-dopamine receptor-containing biochemical compartments and blocks dopamine-dependent receptor internalization.

Authors:  J Christopher Octeau; Joseph M Schrader; Ikuo Masuho; Meenakshi Sharma; Christopher Aiudi; Ching-Kang Chen; Abraham Kovoor; Jeremy Celver
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.